CRAD B Stock Overview
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the America, and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for CRAD B from our risk checks.
C-Rad AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr38.25 |
| 52 Week High | kr49.00 |
| 52 Week Low | kr25.85 |
| Beta | 0.92 |
| 1 Month Change | -4.38% |
| 3 Month Change | -20.31% |
| 1 Year Change | 19.91% |
| 3 Year Change | -33.94% |
| 5 Year Change | -0.52% |
| Change since IPO | 155.00% |
Recent News & Updates
Returns On Capital Are A Standout For C-Rad (STO:CRAD B)
Mar 01
C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem
Feb 15Recent updates
Returns On Capital Are A Standout For C-Rad (STO:CRAD B)
Mar 01C-Rad's (STO:CRAD B) Earnings Are Weaker Than They Seem
Feb 15Do C-Rad's (STO:CRAD B) Earnings Warrant Your Attention?
Feb 03C-Rad AB (publ)'s (STO:CRAD B) Popularity With Investors Is Clear
Jan 19Is Now The Time To Look At Buying C-Rad AB (publ) (STO:CRAD B)?
Oct 28Returns Are Gaining Momentum At C-Rad (STO:CRAD B)
Aug 16Are Investors Undervaluing C-Rad AB (publ) (STO:CRAD B) By 45%?
Dec 14Is Now An Opportune Moment To Examine C-Rad AB (publ) (STO:CRAD B)?
Jul 20Returns Are Gaining Momentum At C-Rad (STO:CRAD B)
May 07Earnings Miss: C-Rad AB (publ) Missed EPS By 5.5% And Analysts Are Revising Their Forecasts
Jan 30C-Rad (STO:CRAD B) Shareholders Will Want The ROCE Trajectory To Continue
Jul 03Will the Promising Trends At C-Rad (STO:CRAD B) Continue?
Mar 05Are C-Rad's (STO:CRAD B) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 07
What Percentage Of C-Rad AB (publ) (STO:CRAD B) Shares Do Insiders Own?
Jan 17Is C-Rad's (STO:CRAD B) 179% Share Price Increase Well Justified?
Dec 13Shareholder Returns
| CRAD B | SE Medical Equipment | SE Market | |
|---|---|---|---|
| 7D | 1.2% | 1.1% | 2.8% |
| 1Y | 19.9% | -5.1% | 13.6% |
Return vs Industry: CRAD B exceeded the Swedish Medical Equipment industry which returned -5.1% over the past year.
Return vs Market: CRAD B exceeded the Swedish Market which returned 13.6% over the past year.
Price Volatility
| CRAD B volatility | |
|---|---|
| CRAD B Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 7.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.8% |
| 10% least volatile stocks in SE Market | 3.6% |
Stable Share Price: CRAD B's share price has been volatile over the past 3 months.
Volatility Over Time: CRAD B's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 87 | Cecilia De Leeuw | www.c-rad.com |
C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the America, and the Asia Pacific. Its products include Sentinel 4DCT, a laser-based optical surface scanning system; Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy, that supports proton therapy from simulation and treatment; and Catalyst+ HD Ring Gantry solution for patient positioning, real-time motion monitoring, and respiratory gating. The company provides Catalyst, a 4D surface guided radiation therapy (SGRT) solution; Catalyst HD, a SGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst PT, a tracking solution for particle therapy; and visual coaching solutions used for prospective and retrospective radiotherapy.
C-Rad AB (publ) Fundamentals Summary
| CRAD B fundamental statistics | |
|---|---|
| Market cap | kr1.29b |
| Earnings (TTM) | kr35.53m |
| Revenue (TTM) | kr424.62m |
36.3x
P/E Ratio3.0x
P/S RatioIs CRAD B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRAD B income statement (TTM) | |
|---|---|
| Revenue | kr424.62m |
| Cost of Revenue | kr137.39m |
| Gross Profit | kr287.23m |
| Other Expenses | kr251.70m |
| Earnings | kr35.53m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 14, 2024
| Earnings per share (EPS) | 1.05 |
| Gross Margin | 67.64% |
| Net Profit Margin | 8.37% |
| Debt/Equity Ratio | 0% |
How did CRAD B perform over the long term?
See historical performance and comparison